{"id":7112,"date":"2018-08-06T10:13:37","date_gmt":"2018-08-06T08:13:37","guid":{"rendered":"https:\/\/filinf.it\/?page_id=7112"},"modified":"2023-06-30T09:59:52","modified_gmt":"2023-06-30T07:59:52","slug":"mrd-network","status":"publish","type":"page","link":"https:\/\/filinf.it\/en\/projects\/mrd-network\/","title":{"rendered":"MRD Network"},"content":{"rendered":"<p><span class=\"TextRun SCXW191908030 BCX0\" lang=\"EN-GB\" xml:lang=\"EN-GB\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW191908030 BCX0\">&#8220;FIL MRD Network&#8221; is a network of\u00a0<\/span><\/span><span class=\"TextRun SCXW191908030 BCX0\" lang=\"EN-GB\" xml:lang=\"EN-GB\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW191908030 BCX0\">laboratories\u00a0<\/span><\/span><span class=\"TextRun SCXW191908030 BCX0\" lang=\"EN-GB\" xml:lang=\"EN-GB\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW191908030 BCX0\">that collaborates for the realization of the minimal residual disease (MRD) studies related to the FIL\u00a0<\/span><\/span><span class=\"TextRun SCXW191908030 BCX0\" lang=\"EN-GB\" xml:lang=\"EN-GB\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW191908030 BCX0\">trials<\/span><\/span><span class=\"TextRun SCXW191908030 BCX0\" lang=\"EN-GB\" xml:lang=\"EN-GB\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW191908030 BCX0\">.<br \/>\nThe biological samples (peripheral blood and bone marrow) of clinical trials patients are centr<\/span><\/span><span class=\"TextRun SCXW191908030 BCX0\" lang=\"EN-GB\" xml:lang=\"EN-GB\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW191908030 BCX0\">alized in the laboratories of the Network, where they carry out analyses.<br \/>\nToday, this network has 4 laboratories which cover all the geographical areas of the national territory.<\/span><\/span><\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-18819 aligncenter\" src=\"https:\/\/filinf.it\/wp-content\/uploads\/2023\/06\/mrd-network-2023_eng.png\" alt=\"\" width=\"813\" height=\"401\" srcset=\"https:\/\/filinf.it\/wp-content\/uploads\/2023\/06\/mrd-network-2023_eng.png 3010w, https:\/\/filinf.it\/wp-content\/uploads\/2023\/06\/mrd-network-2023_eng-300x148.png 300w, https:\/\/filinf.it\/wp-content\/uploads\/2023\/06\/mrd-network-2023_eng-1024x505.png 1024w, https:\/\/filinf.it\/wp-content\/uploads\/2023\/06\/mrd-network-2023_eng-768x379.png 768w, https:\/\/filinf.it\/wp-content\/uploads\/2023\/06\/mrd-network-2023_eng-1536x758.png 1536w, https:\/\/filinf.it\/wp-content\/uploads\/2023\/06\/mrd-network-2023_eng-2048x1010.png 2048w\" sizes=\"(max-width: 813px) 100vw, 813px\" title=\"\"><\/p>\n<p><span class=\"EOP SCXW191908030 BCX0\" data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><span data-contrast=\"auto\">&#8220;FIL MRD Network&#8221; is fundamental to:<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Develop and encourage the management of MRD studies integrated into clinical trials;<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Conduct periodic quality checks (biannual), which ensure the standardization of MRD assessment techniques in lymphomas, so the reproducibility of results between laboratories;<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Build a national biobank;<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Promote the integration of biological elements and of &#8220;Precision Medicine&#8221; in the area of the FIL clinical studies.<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><span data-contrast=\"auto\">Over the last three years (<\/span><b><span data-contrast=\"auto\">2015-2017<\/span><\/b><span data-contrast=\"auto\">), the samples of over 780 patients with follicular lymphoma enrolled in four FIL prospective trials (FOLL12, FLAZ12, RENOIR12, MIRO&#8217;) were centralized.<br \/>\nParticularly, in the studies FOLL12 and MIRO&#8217; the MRD results are used in &#8220;real time&#8221; to address patients to different personalised therapies.<\/span><\/p>\n<p><span data-contrast=\"auto\">MRD analyses are used in another studies, such as R2B, MCL0208, RBAC500 and TRIANGLE (mantle cell lymphoma); BRB (<\/span><span data-contrast=\"auto\">Waldenstrom<\/span><span data-contrast=\"auto\">\u00a0macroglobulinemia).<br \/>\nSince\u00a0<\/span><b><span data-contrast=\"auto\">2018<\/span><\/b><span data-contrast=\"auto\">, the MRD analyses have used in two other studies: RI-CHOP (diffuse large-cell lymphoma B) and V-RBAC (mantle cell lymphoma).<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">In\u00a0<\/span><b><span data-contrast=\"auto\">2018\u00a0<\/span><\/b><span data-contrast=\"auto\">the FIL MRD network laboratories joined the\u00a0<\/span><b><span data-contrast=\"auto\">EuroMRD<\/span><\/b><b><span data-contrast=\"auto\">\u00a0Consortium<\/span><\/b><span data-contrast=\"auto\">\u00a0European group for the standardization of the MRD analysis for lymphomas.<br \/>\nThe\u00a0<\/span><span data-contrast=\"auto\">EuroMRD<\/span><span data-contrast=\"auto\">\u00a0Consortium is a division of the\u00a0<\/span><a href=\"https:\/\/eslho.org\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">ESLHO<\/span><\/a><span data-contrast=\"auto\">\u00a0(European Scientific Foundation for Laboratory\u00a0<\/span><span data-contrast=\"auto\">HematoOncology<\/span><span data-contrast=\"auto\">), in turn the\u00a0<\/span><a href=\"https:\/\/ehaweb.org\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">EHA<\/span><\/a><span data-contrast=\"auto\">&#8216;s official scientific working group (EHA Scientific Working Group, SWG).<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;FIL MRD Network&#8221; is a network of\u00a0laboratories\u00a0that collaborates for the realization of the minimal residual disease (MRD) studies related to&#8230;<\/p>\n","protected":false},"author":10007,"featured_media":7336,"parent":8745,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/pages\/7112"}],"collection":[{"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/users\/10007"}],"replies":[{"embeddable":true,"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/comments?post=7112"}],"version-history":[{"count":0,"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/pages\/7112\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/pages\/8745"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/media\/7336"}],"wp:attachment":[{"href":"https:\/\/filinf.it\/en\/wp-json\/wp\/v2\/media?parent=7112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}